<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">729608</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2022.729608</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Multicomponent Solids of Niflumic and Mefenamic Acids Based on Acid-Pyridine Synthon</article-title>
<alt-title alt-title-type="left-running-head">Kumar et al.</alt-title>
<alt-title alt-title-type="right-running-head">Multicomponent Solids of Niflumic and Mefenamic Acid</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Vineet</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/656539/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goswami</surname>
<given-names>Pramod Kumar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balendra</surname>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/656497/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tewari</surname>
<given-names>Shailabh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/656439/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ramanan</surname>
<given-names>Arunachalam</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/516825/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Chemistry</institution>, <institution>Indian Institute of Technology Delhi</institution>, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Chemistry</institution>, <institution>Sri Venkateswara College</institution>, <institution>University of Delhi</institution>, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1103227/overview">Venu R. Vangala</ext-link>, University of Bradford, United Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1386527/overview">Srinivasulu Aitipamula</ext-link>, Institute of Chemical and Engineering Sciences (A&#x2217;STAR), Singapore</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/120552/overview">Changquan Calvin Sun</ext-link>, University of Minnesota Twin Cities, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Arunachalam Ramanan, <email>aramanan57@gmail.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Solid State Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>729608</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>06</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>02</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Kumar, Goswami, Balendra, Tewari and Ramanan.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Kumar, Goswami, Balendra, Tewari and Ramanan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The present study discusses comparative structural features of fourteen multicomponent solids of two non-steroidal anti-inflammatory drugs, Niflumic and Mefenamic acids, with amine and pyridine-based coformers. All the solids were structurally characterized through PXRD, SCXRD, DSC, and the monophasic nature of some of the solids was established through Rietveld refinement. The solid forms include salt, cocrystal, hydrate, and solvate. Except for two, all the solids reported here showed relatively higher solubility compared to the acids. The difference in p<italic>K</italic>a and similarity in structural features of both the molecules enabled us to study the effect of &#x394;p<italic>K</italic>a on crystallization outcome systematically. The structures of all the solids are described through acid-pyridine synthon perspective.</p>
</abstract>
<kwd-group>
<kwd>cocrystallization</kwd>
<kwd>acid-pyridine synthon</kwd>
<kwd>intermolecular interactions</kwd>
<kwd>&#x394;pKa rule</kwd>
<kwd>hirshfeld surface analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Niflumic acid (Nif) or 2-{[3-(Trifluromethyl)phenyl]amino}nicotinic acid, and Mefenamic acid (Mef) or 2-(2,3-dimethylphenyl) aminobenzoic acid, are non-steroidal anti-inflammatory drugs NSAIDs (<xref ref-type="bibr" rid="B40">Uyemura et al., 1997</xref>; <xref ref-type="bibr" rid="B37">Sturkenboom, 2005</xref>; <xref ref-type="bibr" rid="B20">Khansari and Halliwell, 2009</xref>). These NSAIDs are among the most commonly used pharmaceutical molecules, as analgesic, anti-inflammatory, and antipyretic agents (<xref ref-type="bibr" rid="B11">Dionne and Berthold, 2001</xref>; <xref ref-type="bibr" rid="B13">Garg and Azim, 2021</xref>). Nif and Mef are used to treat various diseases: Nif is used in rheumatoid arthritis, arthrosis, and joint diseases (<xref ref-type="bibr" rid="B38">Sydnes, 1973</xref>), while Mef is prescribed in dental pain, postoperative surgery, premenstrual syndrome, and headache (<xref ref-type="bibr" rid="B3">Bonnar and Sheppard, 1996</xref>). Mef has also shown anti-cancer activity (colon and liver cancer) and therapeutic effect in Alzheimer&#x2019;s disease. Both Nif and Mef (along with Meclofenamic and Tolfenamic acid) belong to a class of NSAIDs called fenamates which are derivatives of anthranilic acid (<xref ref-type="fig" rid="F19">Scheme 1</xref>). Fenamates, generally show poor solubility and high permeability and are classified as Class II drugs as per BCS (Biopharmaceutics Classification System) (<xref ref-type="bibr" rid="B33">SeethaLekshmi and Guru Row, 2012</xref>; <xref ref-type="bibr" rid="B2">Bodn&#xe1;r et al., 2017</xref>). Radacsi et al. used different crystallization techniques: microwave-assisted evaporation, electrospray, and atmospheric pressure cold plasma to improve the bioavailability of Nif (<xref ref-type="bibr" rid="B28">Radacsi et al., 2012a</xref>; <xref ref-type="bibr" rid="B29">Radacsi et al., 2012b</xref>; <xref ref-type="bibr" rid="B30">Radacsi et al., 2013</xref>). Szunyoghet al. tried nanonization of Niflumic acid by co-grinding to improve dissolution rate (<xref ref-type="bibr" rid="B39">Szunyogh et al., 2013</xref>). Wittering et al. employed cocrystallization to prevent polymorphism in fenamates (<xref ref-type="bibr" rid="B42">Wittering et al., 2015</xref>). Recently, Bhattacharya et al. improved solubility of fenamates by formation of drug-drug multicomponent solids with another drug trimethoprim (<xref ref-type="bibr" rid="B1">Bhattacharya et al., 2020</xref>). Moreover, the extensive use of these drugs regularly worldwide led to their presence in wastewater at higher concentrations than the predicted no effect concentration (<xref ref-type="bibr" rid="B25">Margot et al., 2015</xref>; <xref ref-type="bibr" rid="B26">Mila et al., 2019</xref>), and removing them can be a challenging task (<xref ref-type="bibr" rid="B15">Greenstein et al., 2018</xref>). Based on our earlier experience, robust acid-pyridine synthon can be utilized to tune the solubility of these molecules (<xref ref-type="bibr" rid="B21">Kumar et al., 2018</xref>; <xref ref-type="bibr" rid="B14">Goswami et al., 2020</xref>). In the first series, we employed 1,2-bis(4-pyridyl)ethane (<italic>bpe</italic>); 1,2-bis(4-pyridyl)ethylene (<italic>bpee</italic>), and 1,3-di (4-pyridyl)propane (<italic>bpp</italic>) with an objective to systematically vary the spacing and flexibility of 4,4-bipyridyl (<italic>4,4-bpy</italic>), which was earlier used by Wittering et al. as bipyridine are extensively used for the formation of robust material (polymers and membranes), which can further help to remove contaminants from wastewater. In the second series, the three aminopyridines, 2-aminopyridine (<italic>2ap</italic>), 3-aminopyridine (<italic>3ap</italic>), and 4-aminopyridine (<italic>4ap</italic>), were used as coformers to understand the structural chemistry and improve the solubility. Although the amino pyridines do not belong to the GRAS category and out of three <italic>2ap</italic>, (LD50 &#x3d; 200&#xa0;mg/kg in case of rat when used orally) (<xref ref-type="bibr" rid="B34">Shimizu et al., 2000</xref>), <italic>3ap</italic> (LD50 &#x3d; 178&#xa0;mg/kg in case of quail when used orally) (<xref ref-type="bibr" rid="B34">Shimizu et al., 2000</xref>) and <italic>4ap</italic> (LD50 &#x3d; 20&#xa0;mg/kg in case of rat when used orally) (<xref ref-type="bibr" rid="B32">Schafer, 1973</xref>) only the latter is well studied for medicinal use. These commonly used lab chemicals make attractive coformers due to their easy and reliable weak bond formation with a vast range of molecules. A CSD search of Nif showed overall thirty-nine hits, out of which twenty were organic solids. The other NSAID, Mef, showed one hundred and five solids, of which fifty-four were organic solids, of those only 32 and 13 are multicomponent solids, respectively. Fenamates are known to be polymorphic as a consequence of free rotation between the two rings, thus allowing them to have more than one crystal structure (as depicted in <xref ref-type="fig" rid="F20">Scheme 2</xref>); exceptions include a few such as Nif and meclofenamic acid (<xref ref-type="bibr" rid="B8">Delaney et al., 2014</xref>; <xref ref-type="bibr" rid="B24">L&#xf3;pez-Mej&#xed;as and Matzger, 2015</xref>). L&#xf3;pez-Mej&#xed;as et al. discovered six new polymorphs for flufenamic acid; the compound is the second most polymorphic molecule (nine polymorphs) after 5-methyl-2-[(2-nitrophenyl)-amino]thiophene-3-carbonitrile or ROY (thirteen polymorphs) (<xref ref-type="bibr" rid="B23">L&#xf3;pez-Mej&#xed;as et al., 2012</xref>). Uzoh et al. compared crystal energy landscapes of fenamates and showed that conformational flexibility between the two phenyl rings is responsible for this behavior (<xref ref-type="bibr" rid="B41">Uzoh et al., 2012</xref>). Though multicomponent solids of Mef are known with <italic>bpe, bpee, bpp</italic> and <italic>4ap</italic> (<xref ref-type="bibr" rid="B27">Nechipadappu and Trivedi, 2017</xref>; <xref ref-type="bibr" rid="B43">Zheng et al., 2018</xref>), the literature still lacks a comparative study of all these structures and their solubility. A careful analysis of the six selected anthranilic acids with N-based coformers reported in CSD (<xref ref-type="sec" rid="s9">Supplementary Tables S1, S2</xref>) showed acid-pyridine (or N-based co-former) synthon drove the formation of the majority of the multicomponent solids. The table also highlights the need to explore the structural landscape of an acid molecule with a series of structurally related base coformers. Since acid-base interaction is a major driving force, it would be possible to rationalize the composition (A<sub>2</sub>B, AB or AB<sub>2</sub>) occurring at the microlevel and how further supramolecular aggregation to a cocrystal, salt or its solvate is facilitated through the functional groups at the periphery of these aggregates. In <xref ref-type="fig" rid="F21">Scheme 3</xref>, we have given the molecular structure of APIs and coformers used in this study. We employed different crystallization techniques and solvent variations to investigate the structural landscape of the system, acid (Nif or Mef)-N-pyridine based conformer-solvent. In <xref ref-type="table" rid="T1">Table 1</xref>, we have provided the reaction condition for the isolation of the solids reported here.</p>
<fig id="F19" position="float">
<label>SCHEME 1</label>
<caption>
<p>The anthranilic acid derivatives (fenamates) surveyed in this study. The five NSAIDs within the circle have a common anthranilic acid moiety with different substitutions. In case of Flufenamic and Niflumic acids, the difference is the presence of nitrogen instead of carbon in the anthranilic acid ring.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g019.tif"/>
</fig>
<fig id="F20" position="float">
<label>SCHEME 2</label>
<caption>
<p>Polymorphic forms of fenamate derivatives. The substitutions on the phenyl ring are critical in governing the relative orientation of the two aromatic rings which in turn impacts the number of polymorphic forms as well as how it interacts with a coformer under given conditions. Here, Ffa &#x3d; Flufenamic Acid, Ta &#x3d; Tolfenamic Acid, 2-Pna &#x3d; 2-(phenylamino)nicotinic acid, 2-(2-M3ca) &#x3d; 2-(2-Methyl-3-chloroanilino)nicotinic acid, 2-Mana &#x3d; 2-(Mesitylamino)nicotinic acid, Tna &#x3d; 2-(phynylamino)nicotinic acid, and Mef &#x3d; Mefenamic Acid.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g020.tif"/>
</fig>
<fig id="F21" position="float">
<label>SCHEME 3</label>
<caption>
<p>Molecular structure of APIs Niflumic (Nif) and Mefenamic (Mef) acid as well as coformers (<italic>bpe, bpee, bpp,2ap,3ap,</italic> and <italic>4ap</italic>) used in this study.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g021.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Crystallization method used for the synthesis of Nif and Mef based multicomponent solids in the present study and their physical properties. Solids <bold>5</bold>, <bold>6</bold> and <bold>11</bold> could not be isolated as pure phases.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Composition in the solid</th>
<th align="center">Method and solvent of crystallization</th>
<th align="left">Color and morphology</th>
<th align="center">m. p. (&#x00B0;C) (from DSC)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Nif</td>
<td align="left">Used as received</td>
<td align="left">Greenish</td>
<td align="center">203</td>
</tr>
<tr>
<td align="left">Mef</td>
<td align="left">Used as received</td>
<td align="left">Colorless</td>
<td align="center">230</td>
</tr>
<tr>
<td align="left">(Nif)<sub>2</sub>&#xb7;(bpe) (1)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, colorless</td>
<td align="center">177</td>
</tr>
<tr>
<td align="left">(Nif)<sub>2</sub>&#xb7;(bpee) (2)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Block, green</td>
<td align="center">179</td>
</tr>
<tr>
<td align="left">(Nif)<sub>2</sub>&#xb7;(bpee).1,4-dioxane (2a)</td>
<td align="left">1,4- dioxane assisted grinding, 1,4- dioxane</td>
<td align="left">Rod, green</td>
<td align="center">178</td>
</tr>
<tr>
<td align="left">(Nif)<sub>2</sub>&#xb7;(bpp) (3)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, colorless</td>
<td align="center">92</td>
</tr>
<tr>
<td align="left">(Nif)<sup>&#x2212;</sup>&#xb7;(2apH)<sup>&#x2b;</sup>(4)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, yellow</td>
<td align="center">123</td>
</tr>
<tr>
<td align="left">(Nif)<sup>&#x2212;</sup>&#xb7;(2apH)<sup>&#x2b;</sup>(4a)</td>
<td align="left">Neat grinding, acetone assisted grinding, acetone</td>
<td align="left">Rod, yellow</td>
<td align="center">124</td>
</tr>
<tr>
<td align="left">(Nif)<sup>&#x2212;</sup>&#xb7;(3apH)<sup>&#x2b;</sup>(5)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, yellow</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">(Nif)<sup>&#x2212;</sup>&#xb7;(4apH)<sup>&#x2b;</sup>(6)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, colorless</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">(Mef)<sub>2</sub>&#xb7;(bpe) (7)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, colorless</td>
<td align="center">188</td>
</tr>
<tr>
<td align="left">(Mef)<sub>2</sub>&#xb7;(bpee) (8)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Rod, green</td>
<td align="center">216</td>
</tr>
<tr>
<td align="left">Mef&#xb7;bpp (9)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Block, colorless</td>
<td align="center">192</td>
</tr>
<tr>
<td align="left">(Mef)&#xb7;(2apH)<sup>&#x2b;</sup>&#xb7;H<sub>2</sub>O (10)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Block, red</td>
<td align="center">118</td>
</tr>
<tr>
<td align="left">Mef&#xb7;<italic>3ap</italic> (11)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Block, colorless</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">(Mef)<sup>&#x2212;</sup>&#xb7;(4apH)<sup>&#x2b;</sup>&#xb7;H<sub>2</sub>O (12)</td>
<td align="left">Neat grinding, methanol assisted grinding, methanol</td>
<td align="left">Block, colorless</td>
<td align="center">125</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<p>All the reagents (Nif, Mef, <italic>bpe</italic>, <italic>bpee</italic>, <italic>bpp</italic>, <italic>2ap, 3ap,</italic> and <italic>4ap</italic>) were purchased from Sigma-Aldrich and were used as received.</p>
<sec id="s2-1">
<title>Mechanochemical Reaction</title>
<p>The method was used to prepare new solid forms of Nif and Mef based molecules. API and coformer were ground in an agate mortar, either neat or in the presence of two drops of solvent (acetone/methanol/1,4-dioxane). PXRD was used to confirm the formation of the new phase. Good quality crystals suitable for SCXRD were grown by dissolving the powder in a suitable solvent (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
<sec id="s2-2">
<title>Solvent Evaporation</title>
<p>Both API (1&#xa0;mM) and conformer (1&#xa0;mM) was dissolved in an appropriate solvent (2&#xa0;ml) with gentle stirring till a transparent solution was obtained (usually 10&#x2013;15&#xa0;min). The clear solution was kept for crystallization at room temperature. In most cases, good-quality crystals were filtered after seven to 10&#xa0;days. Ten new and four previously reported multicomponent solids of Nif and Mef were isolated in this study. Crystal data and structure refinement are summarized in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Crystal data and structure refinement of the solids <bold>1</bold>&#x2012;<bold>12.</bold>
</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th align="center">
<bold>1</bold>
</th>
<th align="center">
<bold>2</bold>
</th>
<th align="center">
<bold>2a</bold>
</th>
<th align="center">
<bold>3</bold>
</th>
<th align="center">
<bold>4</bold>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Empirical formula</td>
<td align="center">C38 H30 F6 N6 O4</td>
<td align="center">C19 H14 F3 N3 O2</td>
<td align="center">C21 H18 F3 N3 O3</td>
<td align="center">C39 H32 F6 N6 O4</td>
<td align="center">C18 H15 F3 N4 O2</td>
</tr>
<tr>
<td align="left">Formula weight</td>
<td align="center">748.68</td>
<td align="center">373.33</td>
<td align="center">417.38</td>
<td align="center">762.71</td>
<td align="center">376.34</td>
</tr>
<tr>
<td align="left">Temperature (K)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
</tr>
<tr>
<td align="left">Crystal system</td>
<td align="center">Monoclinic</td>
<td align="center">Monoclinic</td>
<td align="center">Triclinic</td>
<td align="center">Monoclinic</td>
<td align="center">Monoclinic</td>
</tr>
<tr>
<td align="left">Space group</td>
<td align="center">
<italic>P</italic>2<sub>1</sub>/n</td>
<td align="center">
<italic>C</italic>c</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>C</italic> 2/c</td>
<td align="center">
<italic>C</italic>c</td>
</tr>
<tr>
<td align="left">
<italic>a</italic> (&#xc5;)</td>
<td align="center">10.6728 (16)</td>
<td align="center">25.380 (6)</td>
<td align="center">9.355 (5)</td>
<td align="center">17.889 (4)</td>
<td align="center">7.413 (2)</td>
</tr>
<tr>
<td align="left">
<italic>b</italic> (&#xc5;)</td>
<td align="center">12.4719 (19)</td>
<td align="center">12.495 (3)</td>
<td align="center">10.722 (6)</td>
<td align="center">7.4942 (18)</td>
<td align="center">33.061 (10)</td>
</tr>
<tr>
<td align="left">
<italic>c</italic> (&#xc5;)</td>
<td align="center">25.232 (4)</td>
<td align="center">10.764 (3)</td>
<td align="center">11.110 (6)</td>
<td align="center">28.063(6)</td>
<td align="center">7.690 (2)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b1;</italic> (&#xb0;)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
<td align="center">67.844 (11)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b2;</italic> (&#xb0;)</td>
<td align="center">92.169 (3)</td>
<td align="center">92.040 (5)</td>
<td align="center">79.027 (12)</td>
<td align="center">104.669 (5)</td>
<td align="center">109.745 (6)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b3;</italic> (&#xb0;)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
<td align="center">75.084 (11)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
</tr>
<tr>
<td align="left">V (&#xc5;<sup>3</sup>)</td>
<td align="center">3356.3 (9)</td>
<td align="center">3411.4 (13)</td>
<td align="center">991.9 (9)</td>
<td align="center">3639.6 (14)</td>
<td align="center">1773.8 (9)</td>
</tr>
<tr>
<td align="left">Z</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">D<sub>calc</sub>, (gcm<sup>&#x2212;3</sup>)</td>
<td align="center">1.482</td>
<td align="center">1.454</td>
<td align="center">1.398</td>
<td align="center">1.392</td>
<td align="center">1.409</td>
</tr>
<tr>
<td align="left">&#xb5;MoK&#x3b1; (cm<sup>&#x2212;1</sup>)</td>
<td align="center">0.121</td>
<td align="center">0.119</td>
<td align="center">0.114</td>
<td align="center">0.113</td>
<td align="center">0.116</td>
</tr>
<tr>
<td align="left">Goodness-of-fit (GOF) on <italic>F</italic>
<sup>2</sup>
</td>
<td align="center">1.073</td>
<td align="center">1.025</td>
<td align="center">0.998</td>
<td align="center">1.160</td>
<td align="center">1.060</td>
</tr>
<tr>
<td align="left">
<italic>&#x3bb;</italic> (&#xc5;)</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
</tr>
<tr>
<td align="left">R<sub>1,</sub>
<italic>w</italic>R<sub>2</sub>[I &#x3e; 2&#x3c3; (<italic>I</italic>)]<sup>a</sup>
</td>
<td align="center">0.0684,0.1524</td>
<td align="center">0.0896,0.1461</td>
<td align="center">0.0902,0.2861</td>
<td align="center">0.0881,0.2493</td>
<td align="center">0.0429,0.1119</td>
</tr>
<tr>
<td align="left">CCDC</td>
<td align="center">1574267</td>
<td align="center">1574270</td>
<td align="center">1574266</td>
<td align="center">1574275</td>
<td align="center">1574269</td>
</tr>
</tbody>
</table>
<table>
<tbody valign="top">
<tr>
<td align="left">&#x2014;</td>
<td align="center">
<bold>4a</bold>
</td>
<td align="center">
<bold>5</bold>
</td>
<td align="center">
<bold>6</bold>
</td>
<td align="center">
<bold>7</bold>
</td>
<td align="center">
<bold>8</bold>
</td>
</tr>
<tr>
<td align="left">Empirical formula</td>
<td align="center">C18 H15 F3 N4 O2</td>
<td align="center">C18 H15 F3 N4 O2</td>
<td align="center">C18 H15 F3 N4 O2</td>
<td align="center">C21 H21 N2 O2</td>
<td align="center">C21 H20 N2 O2</td>
</tr>
<tr>
<td align="left">Formula weight</td>
<td align="center">376.34</td>
<td align="center">376.34</td>
<td align="center">376.34</td>
<td align="center">333.40</td>
<td align="center">332.39</td>
</tr>
<tr>
<td align="left">Temperature (K)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
</tr>
<tr>
<td align="left">crystal system</td>
<td align="center">Triclinic</td>
<td align="center">Orthorhombic</td>
<td align="center">Monoclinic</td>
<td align="center">Triclinic</td>
<td align="center">Triclinic</td>
</tr>
<tr>
<td align="left">Space group</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>Pbca</italic>
</td>
<td align="center">
<italic>C</italic>c</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
</tr>
<tr>
<td align="left">
<italic>a</italic> (&#xc5;)</td>
<td align="center">8.0525 (5)</td>
<td align="center">7.8043 (3)</td>
<td align="center">14.6959 (16)</td>
<td align="center">7.783 (2)</td>
<td align="center">7.814 (2)</td>
</tr>
<tr>
<td align="left">
<italic>b</italic> (&#xc5;)</td>
<td align="center">8.1125 (5)</td>
<td align="center">12.2520 (5)</td>
<td align="center">10.4708 (16)</td>
<td align="center">8.866 (3)</td>
<td align="center">8.787 (2)</td>
</tr>
<tr>
<td align="left">
<italic>c</italic> (&#xc5;)</td>
<td align="center">25.6798 (18)</td>
<td align="center">34.9035 (15)</td>
<td align="center">22.935 (3)</td>
<td align="center">13.261 (4)</td>
<td align="center">13.111 (3)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b1;</italic> (&#xb0;)</td>
<td align="center">87.750 (2)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
<td align="center">101.121 (5)</td>
<td align="center">99.996 (5)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b2;</italic> (&#xb0;)</td>
<td align="center">83.626 (2)</td>
<td align="center">90.00</td>
<td align="center">95.197 (3)</td>
<td align="center">98.179 (6)</td>
<td align="center">98.722 (5)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b3;</italic> (&#xb0;)</td>
<td align="center">89.763 (2)</td>
<td align="center">90.00</td>
<td align="center">90.00</td>
<td align="center">92.780 (5)</td>
<td align="center">92.125 (6)</td>
</tr>
<tr>
<td align="left">V (&#xc5;<sup>3</sup>)</td>
<td align="center">1665.90 (19)</td>
<td align="center">3337.4 (2)</td>
<td align="center">3514.8 (8)</td>
<td align="center">886.0 (5)</td>
<td align="center">874.4 (4)</td>
</tr>
<tr>
<td align="left">Z</td>
<td align="center">4</td>
<td align="center">8</td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">D<sub>calc</sub>, (gcm<sup>&#x2212;3</sup>)</td>
<td align="center">1.500</td>
<td align="center">1.498</td>
<td align="center">1.422</td>
<td align="center">1.250</td>
<td align="center">1.263</td>
</tr>
<tr>
<td align="left">&#xb5;MoK&#x3b1; (cm<sup>&#x2212;1</sup>)</td>
<td align="center">0.123</td>
<td align="center">0.123</td>
<td align="center">0.117</td>
<td align="center">0.081</td>
<td align="center">0.082</td>
</tr>
<tr>
<td align="left">Goodness-of-fit (GOF) on <italic>F</italic>
<sup>2</sup>
</td>
<td align="center">1.057</td>
<td align="center">0.958</td>
<td align="center">1.075</td>
<td align="center">1.145</td>
<td align="center">1.078</td>
</tr>
<tr>
<td align="left">
<italic>&#x3bb;</italic> (&#xc5;)</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
</tr>
<tr>
<td align="left">R<sub>1,</sub>
<italic>w</italic>R<sub>2</sub>[I &#x3e; 2&#x3c3;(<italic>I</italic>)]<sup>a</sup>
</td>
<td align="center">0.0459, 0.1227</td>
<td align="center">0.0408, 0.1328</td>
<td align="center">0.0705, 0.1828</td>
<td align="center">0.0799, 0.1901</td>
<td align="center">0.0740, 0.1943</td>
</tr>
<tr>
<td align="left">CCDC</td>
<td align="center">1574277</td>
<td align="center">2089680</td>
<td align="center">1574268</td>
<td align="center">1574274</td>
<td align="center">1574271</td>
</tr>
</tbody>
</table>
<table>
<tbody valign="top">
<tr>
<td align="left">&#x2014;</td>
<td align="center">
<bold>9</bold>
</td>
<td align="center">
<bold>10</bold>
</td>
<td align="center">
<bold>11</bold>
</td>
<td align="center">
<bold>12</bold>
</td>
</tr>
<tr>
<td align="left">Empirical formula</td>
<td align="center">C28 H29 N3 O2</td>
<td align="center">C20 H23 N3 O3</td>
<td align="center">C20 H21 N3 O2</td>
<td align="center">C20 H23 N3 O3</td>
</tr>
<tr>
<td align="left">Formula weight</td>
<td align="center">439.54</td>
<td align="center">353.41</td>
<td align="center">335.40</td>
<td align="center">353.41</td>
</tr>
<tr>
<td align="left">Temperature (K)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
<td align="center">298 (2)</td>
</tr>
<tr>
<td align="left">crystal system</td>
<td align="center">Triclinic</td>
<td align="center">Triclinic</td>
<td align="center">Triclinic</td>
<td align="center">Monoclinic</td>
</tr>
<tr>
<td align="left">Space group</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>P</italic> &#x12b;</td>
<td align="center">
<italic>P</italic>2<sub>1</sub>/n</td>
</tr>
<tr>
<td align="left">
<italic>a</italic> (&#xc5;)</td>
<td align="center">7.675 (3)</td>
<td align="center">7.954 (3)</td>
<td align="center">6.0177 (5)</td>
<td align="center">7.785 (2)</td>
</tr>
<tr>
<td align="left">
<italic>b</italic> (&#xc5;)</td>
<td align="center">7.828 (3)</td>
<td align="center">8.027 (3)</td>
<td align="center">11.1933 (9)</td>
<td align="center">8.359 (2)</td>
</tr>
<tr>
<td align="left">
<italic>c</italic> (&#xc5;)</td>
<td align="center">20.462 (7)</td>
<td align="center">15.822(5)</td>
<td align="center">13.7316 (13)</td>
<td align="center">28.691 (8)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b1;</italic> (&#xb0;)</td>
<td align="center">88.438 (7)</td>
<td align="center">83.883 (7)</td>
<td align="center">79.420 (4)</td>
<td align="center">90.00</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b2;</italic> (&#xb0;)</td>
<td align="center">86.370 (6)</td>
<td align="center">85.659 (7)</td>
<td align="center">78.913 (4)</td>
<td align="center">95.470 (6)</td>
</tr>
<tr>
<td align="left">
<italic>&#x3b3;</italic> (&#xb0;)</td>
<td align="center">79.737 (7)</td>
<td align="center">66.931 (7)</td>
<td align="center">75.134 (3)</td>
<td align="center">90.00</td>
</tr>
<tr>
<td align="left">V (&#xc5;<sup>3</sup>)</td>
<td align="center">1207.2 (7)</td>
<td align="center">923.5 (6)</td>
<td align="center">868.45 (13)</td>
<td align="center">1858.5 (9)</td>
</tr>
<tr>
<td align="left">Z</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">D<sub>calc</sub>, (g cm<sup>&#x2212;3</sup>)</td>
<td align="center">1.209</td>
<td align="center">1.271</td>
<td align="center">1.283</td>
<td align="center">1.263</td>
</tr>
<tr>
<td align="left">&#xb5;MoK&#x3b1; (cm<sup>&#x2212;1</sup>)</td>
<td align="center">0.077</td>
<td align="center">0.087</td>
<td align="center">0.084</td>
<td align="center">0.086</td>
</tr>
<tr>
<td align="left">Goodness-of-fit (GOF) on <italic>F</italic>
<sup>2</sup>
</td>
<td align="center">0.917</td>
<td align="center">1.111</td>
<td align="center">1.083</td>
<td align="center">1.031</td>
</tr>
<tr>
<td align="left">
<italic>&#x3bb;</italic> (&#xc5;)</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
<td align="center">0.71073</td>
</tr>
<tr>
<td align="left">R<sub>1,</sub> <italic>w</italic>R<sub>2</sub>[I &#x3e; 2&#x3c3;(<italic>I</italic>)]<sup>a</sup>
</td>
<td align="center">0.0503, 0.1790</td>
<td align="center">0.0936, 0.2462</td>
<td align="center">0.0517, 0.1471</td>
<td align="center">0.0700, 0.2244</td>
</tr>
<tr>
<td align="left">CCDC</td>
<td align="center">1574272</td>
<td align="center">1574273</td>
<td align="center">2089681</td>
<td align="center">2089918</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-3">
<title>X-Ray Structure Determination</title>
<p>X-ray diffraction studies of crystals mounted on a capillary were carried out on a BRUKER AXS SMART-APEX diffractometer with a CCD area detector (MoK&#x3b1; &#x3d; 0.71073&#xa0;&#xc5;, monochromator: graphite) (<xref ref-type="bibr" rid="B4">Bruker Analytical X-ray Systems, 2000</xref>, SMART: Bruker Molecular Analysis Research Tool, Madison, WI, 2000). Frames were collected at T &#x3d; 298&#xa0;K by &#x3c9;, &#x3d5; and 2&#x3b8;-rotation at 10&#xa0;s per frame with SAINT (<xref ref-type="bibr" rid="B5">Bruker Analytical X-ray Systems, SAINT-NT., 2001</xref>). The measured intensities were reduced to F<sup>2</sup> and corrected for absorption with SADABS (<xref ref-type="bibr" rid="B5">Bruker Analytical X-ray Systems, 2001, SAINT-NT., 2001</xref>). Structure solution, refinement, and data output were carried out with the SHELXTL program suite on the Olex-2 platform (<xref ref-type="bibr" rid="B12">Dolomanov et al., 2009</xref>). Non-hydrogen atoms were refined anisotropically. C&#x2212;H hydrogen atoms were placed in geometrically calculated positions by using a riding model. O&#x2212;H and N&#x2212;H hydrogen atoms were localized by difference Fourier maps and refined in subsequent refinement cycles. Images were created with Crystal Impact Diamond software ((<xref ref-type="bibr" rid="B17">Putz et al., nd</xref>) Visual Crystal Structure Information, <ext-link ext-link-type="uri" xlink:href="http://www.ccp14.ac.uk/ccp/web-mirrors/crystalimpact/diamond/publ/jac">http://www.ccp14.ac.uk/ccp/web-mirrors/crystalimpact/diamond/publ/jac</ext-link>). Hydrogen bonding interactions in the crystal lattice were calculated with SHELXTL.</p>
</sec>
<sec id="s2-4">
<title>Solubility Studies</title>
<p>Solubility of all multicomponent solids reported here was determined using UV-Vis method reported by Choudhury et al. (<xref ref-type="bibr" rid="B19">Karanam and Choudhury, 2013</xref>; <xref ref-type="bibr" rid="B18">Joshi and Roy Choudhury, 2018</xref>), and Higuchi and Connor in 1965 (<xref ref-type="bibr" rid="B16">Higuchi and Connors, 1965</xref>). A measured quantity of each solid was completely dissolved in a large excess of distilled water (pH &#x3d; 6.8). The stock solutions were suitably diluted to get absorbance values within 1 in the UV-vis spectrum and to prepare standard solutions for generating the calibration curves. The &#x3bb;<sub>max</sub> values of Nif/Mef in all the salts were then determined using a PerkinElmer Lambda 1050 UV/Vis/NIR spectrophotometer with a quartz cuvette. The absorbance values of the primary standard solutions were determined at the respective &#x3bb;<sub>max</sub> values. The absorbance values were plotted in the y-axis, and the concentrations were plotted in the x-axis, and the points were fitted to a straight line (calibration curve). Simultaneously, a suspension of Nif/Mef in distilled water was stirred at room temperature for 24&#xa0;h. The excess solids were filtered, and the solution was diluted to get the absorbance value within 1 in the UV-vis spectrum. PXRD analysis of the residual solids was carried out to assess the nature of the solid forms. The absorbance of the clear diluted solution was determined at &#x3bb;<sub>max</sub> of Nif/Mef for all solids, and the concentration of the salt was determined using the calibration curve, which was generated earlier. The solubility of all the solids was measured at 33&#xb0;C. The solubility was calculated by multiplying the concentration of the dilute solution by 1,000.</p>
<p>Solubility of all the salts and cocrystals reported in this study was measured and compared with free acids in similar conditions. Crystalline salts of Nif and Mef showed considerable improvement in solubility with aminopyridine coformers compared with bipyridine coformers. In the case of Nif based solids, the salt of Nif with <italic>2ap</italic> coformer showed higher solubility while the cocrystals of Nif with <italic>bpe</italic> and <italic>bpee</italic> exhibited a decrease in solubility. The salt of <italic>2ap</italic> with Mef showed the most remarkable solubility improvement among Mef based solids, while <italic>bpe</italic> and <italic>bpee</italic> based solids showed only marginal improvement. We were unsuccessful to correlate the solubility with the percentage of occurrence of various noncovalent interactions. The solubility trends for Nif and Mef based multicomponent solids have been depicted in <xref ref-type="sec" rid="s9">Supplementary Figure S3</xref>. Solubility of the solids <bold>4a, 5,</bold> and <bold>11</bold> were not measured due to lack of purity in the samples.</p>
</sec>
<sec id="s2-5">
<title>Other Physical Measurements</title>
<p>DSC analysis was carried out using a PerkinElmer DSC system on well-ground samples under a nitrogen atmosphere at the rate of 10&#xb0;C min<sup>&#x2212;1</sup>. Room-temperature powder X-ray diffraction data were collected on a Bruker D8 Advance diffractometer using Ni-filtered CuK&#x3b1; radiation. Data were collected with a step size of 0.05 and at a count time of 1&#xa0;s per step over the range 10&#xb0; &#x3c; 2&#x3b8; &#x3c; 50&#xb0;. A Rietveld treatment of the powder diffraction data of the powder sample was carried out based on single-crystal data using TOPAS 4.2, Bruker to ascertain the homogeneity of the bulk sample (<xref ref-type="sec" rid="s9">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B10">Coelho, 2018</xref>, <ext-link ext-link-type="uri" xlink:href="https://www.bruker.com/products/x-ray-diffraction-and-elemental-analysis/x-ray-diffraction/xrd-software/topas.html">https://www.bruker.com/products/x-ray-diffraction-and-elemental-analysis/x-ray-diffraction/xrd-software/topas.html</ext-link>).</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<p>The robust acid-pyridine synthon is the main driving force for the formation of multicomponent solids. In some solids, a proton was transferred from acid to pyridine; in selected cases, solvent/water molecule was included in the crystal. Although &#x3c0;&#x2219;&#x2219;&#x2219;&#x3c0;, C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0;, and C&#x2500;F&#x2219;&#x2219;&#x2219;H&#x2500;C interaction played a significant role in the structure formation of all the solids, acid-pyridine synthon remained decisive in dictating the crystal structures. All major synthons involved in this study are shown in <xref ref-type="fig" rid="F22">Scheme 4</xref>. In this system, variation of composition and solvent affected the outcome of crystallization only in two cases. In general, bipyridine coformers, namely, <italic>bpe, bpee,</italic> and <italic>bpp,</italic> yielded solids with 2:1 composition as the trimeric acid-pyridine synthon is the main driving force for the supramolecular aggregation. However, solvent variation led to two exceptions: solvated Nif<italic>bpee</italic> and salt polymorphs Nif&#xb7;<italic>2ap</italic>. In the case of aminopyridines as coformers, the outcome of crystallization was a 1:1 salt with Nif based solids. Interestingly, Mef based solids resulted in the form of salt monohydrates.</p>
<fig id="F22" position="float">
<label>SCHEME 4</label>
<caption>
<p>Different types of synthons as observed in the solids <bold>1-12.</bold>
</p>
</caption>
<graphic xlink:href="fchem-10-729608-g022.tif"/>
</fig>
<sec id="s3-1">
<title>Crystal Structure of Bipyridine Based Solids</title>
<p>Bipyridine-based coformers like <italic>bpe</italic>, <italic>bpee</italic> and <italic>bpp</italic> formed solids <bold>1</bold>, <bold>2</bold>, <bold>2a</bold> and <bold>3</bold> with Nif and <bold>7</bold>, <bold>8,</bold> and <bold>9</bold> with Mef. The reaction of Nif and <italic>bpe</italic> formed a 2:1 cocrystal <bold>1,</bold> where two molecules of Nif and one molecule of <italic>bpe</italic> are present in the asymmetric unit. In <bold>1</bold>, the trimer Nif&#x2013;<italic>bpe</italic>&#x2013;Nif, driven by acid-pyridine planar heterosynthon I (<xref ref-type="fig" rid="F22">Scheme 4</xref>), is the main building block. The trimers interact through C&#x2500;H&#x2219;&#x2219;&#x2219;N (3.08&#xa0;&#xc5;) and C&#x2500;H&#x2219;&#x2219;&#x2219;F (2.591, 3.022, 2.807, and 3.486&#xa0;&#xc5;), forming a 2D planar sheet (<xref ref-type="fig" rid="F1">Figure 1</xref>). Nif cocrystallized with <italic>bpee,</italic> forming a 2:1 cocrystal <bold>2,</bold> which is isostructural with solid <bold>1</bold>. In <bold>2</bold>, Nif&#x2500;<italic>bpee</italic>&#x2500;Nif trimers connect with each other through C&#x2500;H&#x2219;&#x2219;&#x2219;N (3.143&#xa0;&#xc5;) and C&#x2500;H&#x2219;&#x2219;&#x2219;F (2.653, 3.652, 2.653, and 3.652&#xa0;&#xc5;) interactions (<xref ref-type="fig" rid="F2">Figure 2</xref>). The reaction of Nif with <italic>bpee</italic> in 1,4-dioxane as solvent formed solid <bold>2a.</bold> The only difference between the structure of <bold>2a</bold> and the previous two solids is the inclusion of 1,4-dioxane solvent in the crystal structure. In <bold>2a</bold>, two trimers are bridged through 1,4-dioxane via C&#x2500;H-F (2.669&#xa0;&#xc5;) instead of a ring formation (<xref ref-type="fig" rid="F2">Figure 2</xref>). The reaction of Nif with <italic>bpp</italic> formed a 2:1 cocrystal <bold>3</bold> with one molecule of Nif and half a molecule of <italic>bpp</italic> in the asymmetric unit. The trimer formed with acid-pyridine synthon again connected through C&#x2500;H&#x2219;&#x2219;&#x2219;F (2.580&#xa0;&#xc5; and 2.760&#xa0;&#xc5;), resulting in a planar sheet; the sheets are further linked via other C&#x2500;H&#x2219;&#x2219;&#x2219;F (3.442&#xa0;&#xc5;) interactions (<xref ref-type="fig" rid="F3">Figure 3</xref>). C&#x2500;H&#x2219;&#x2219;&#x2219;N interactions formed by the nitrogen of the pyridyl group in Nif were also observed in the solids <bold>1</bold>, <bold>2</bold> and <bold>2a</bold> but were absent in <bold>3</bold>. The reaction of Mef with <italic>bpe</italic> and <italic>bpee</italic> formed two isostructural solids <bold>7</bold> and <bold>8</bold>. The acid&#x2219;&#x2219;&#x2219;pyridine heterosynthon I (<xref ref-type="fig" rid="F22">Scheme 4</xref>) was the major synthon as expected. In both the solids, the trimers are connected through the C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; bond (3.435 and 3.367&#xa0;&#xc5;) with other trimers on the <italic>bc</italic>-plane, forming a three-dimensional network (<xref ref-type="fig" rid="F4">Figure 4</xref>). Interestingly, cocrystallization of Mef with <italic>bpp</italic> yielded <bold>9</bold>, wherein a dimer was the building block instead of the usual trimer. The asymmetric unit showed the presence of one molecule of Mef and <italic>bpp</italic> each. The other pyridine nitrogen of the dimer interacted with the other dimer via C&#x2500;H&#x2219;&#x2219;&#x2219;N (2.899&#xa0;&#xc5;) interaction, forming a planar sheet (<xref ref-type="fig" rid="F5">Figure 5A</xref>). The sheets are stacked one over the other via C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; (2.879, 2.933 and 2.897&#xa0;&#xc5;) and C&#x2500;H&#x2219;&#x2219;&#x2219;N (2.837&#xa0;&#xc5;) interactions (<xref ref-type="fig" rid="F5">Figure 5B</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Nif&#x2500;<italic>bpe</italic>&#x2500;Nif trimers are interacted <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;N (synthon VII) and C&#x2500;H&#x2219;&#x2219;&#x2219;F interaction, forming a planar sheet.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>In <bold>2</bold> and <bold>2a</bold>, Nif&#x2500;<italic>bpee</italic>&#x2500;Nif trimers are interconnected via C&#x2500;H&#x2219;&#x2219;&#x2219;N and C&#x2500;H&#x2219;&#x2219;&#x2219;F interactions, forming a planar sheet.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> In <bold>3</bold>, Nif&#x2500;<italic>bpp</italic>&#x2500;Nif trimers are connected with other trimers forming a planar sheet <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;F interaction. <bold>(B)</bold> Different sheets further connect via other C&#x2500;H&#x2219;&#x2219;&#x2219;F interactions to form a 3D structure.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<bold>(A)</bold> Mef&#x2500;<italic>bpe</italic>&#x2500;Mef trimers are connected with other trimers via C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; interaction in <bold>7</bold>. <bold>(B)</bold> Isostructural <bold>8</bold> shows the same types of Mef&#x2500;<italic>bpee</italic>&#x2500;Mef trimers interactions.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> Nif&#x2500;bpp dimers interconnected <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;N forming a planar sheet in <bold>9</bold>. <bold>(B)</bold> Planar sheets <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; and C&#x2500;H&#x2219;&#x2219;&#x2219;N interaction are stacked one over the other, forming a 3D structure.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g005.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Crystal Structures of Aminopyridine Based Solids</title>
<p>The use of aminopyridine coformers <italic>2ap, 3ap,</italic> and <italic>4ap</italic> with Nif led to the isolation of the solids <bold>4</bold>, <bold>4a</bold>, <bold>5,</bold> and <bold>6</bold> while Mef yielded the solids <bold>10, 11,</bold> and <bold>12.</bold> The reaction of Nif and <italic>2ap</italic> formed a 1:1 salt <bold>4</bold> and its solvate, <bold>4a</bold>. In <bold>4</bold>, one molecule each of Nif and <italic>2ap</italic> is present in the asymmetric unit. In the dimer formed between Nif and <italic>2ap</italic>, the proton transfer from the oxygen of the carboxylate group in Nif to nitrogen of pyridyl group in <italic>2ap</italic> ensured the heterosynthon III (<xref ref-type="fig" rid="F22">Scheme 4</xref>) as the main building block. These dimers are connected to each other via N&#x2500;H&#x2219;&#x2219;&#x2219;O (2.058&#xa0;&#xc5;), where the amino group of <italic>2ap</italic> and the other oxygen of carboxylate acting as donor and acceptor, respectively, forming 1D H-bonded chains (<xref ref-type="fig" rid="F6">Figure 6A</xref>); the chains are further interconnected via C&#x2500;H&#x2219;&#x2219;&#x2219;F (2.669 and 2.586&#xa0;&#xc5;) to form a 3D network (<xref ref-type="fig" rid="F6">Figure 6B</xref>). The salt solvate <bold>4a</bold> was isolated when crystallization was carried out in a different solvent (<xref ref-type="table" rid="T1">Table 1</xref>). In <bold>4a</bold>, two molecules, each of Nif and <italic>2ap,</italic> are present in the asymmetric unit. The dimer formed through the heterosynthon III (N&#x2500;H&#x2219;&#x2219;&#x2219;O: 2.647 and 2.857&#xa0;&#xc5;) (<xref ref-type="fig" rid="F22">Scheme 4</xref>) is the main building block. The dimers are further connected via heterosynthon IV (N&#x2500;H&#x2219;&#x2219;&#x2219;O: 2.871&#xa0;&#xc5;) (<xref ref-type="fig" rid="F22">Scheme 4</xref>), forming a tetramer (<xref ref-type="fig" rid="F7">Figure 7A</xref>). These tetramers are stacked one over the other through C&#x2212;H&#x2219;&#x2219;&#x2219;&#x3c0; interactions (3.242 and 3.581&#xa0;&#xc5;) forming a layer; these layers cross-link each other <italic>via</italic> C&#x2212;H&#x2219;&#x2219;&#x2219;F (3.682&#xa0;&#xc5;) interactions (<xref ref-type="fig" rid="F7">Figure 7B</xref>). Solid <bold>5</bold> contains one molecule each of Nif and <italic>3ap</italic> in the asymmetric unit. The solid <bold>6</bold> formed by the reaction of Nif and <italic>4ap</italic>, where again dimer formation took place via heterosynthon V (<xref ref-type="fig" rid="F22">Scheme 4</xref>), which are further connected with other dimers through N&#x2500;H&#x2219;&#x2219;&#x2219;O (2.228&#xa0;&#xc5;), C&#x2500;H&#x2219;&#x2219;&#x2219;F (2.605&#xa0;&#xc5;), and N&#x2500;H&#x2219;&#x2219;&#x2219;O (2.228&#xa0;&#xc5;) through the oxygen of the carboxylate moiety of Nif and the amine moiety of <italic>4ap</italic>, forming a chain. These chains are further connected with other chains in a perpendicular fashion via C&#x2500;H&#x2219;&#x2219;&#x2219;O (2.495&#xa0;&#xc5;) and N&#x2500;H&#x2219;&#x2219;&#x2219;O (2.311&#xa0;&#xc5;) interactions, forming a 3D network (<xref ref-type="fig" rid="F8">Figure 8</xref>). Interestingly, the reaction of Mef with aminopyridine coformers <italic>2ap, 3ap,</italic> and <italic>4ap</italic> formed two salt hydrates <bold>(</bold>solids <bold>10</bold> and <bold>12)</bold> with the composition 1:1:1 and a cocrystal (solid <bold>11</bold>) with the composition 1:1. In <bold>10,</bold> Mef and <italic>2ap</italic> formed a dimer via synthon III (<xref ref-type="fig" rid="F22">Scheme 4</xref>) like in <bold>4</bold>. However, interaction of the dimers was facilitated via water molecules through N&#x2500;H&#x2219;&#x2219;&#x2219;O (2.007&#xa0;&#xc5;) forming a chain. It should be noted that a similar observation was not found in Nif&#xb7;<italic>2ap</italic>, solid <bold>4</bold>. These two chains are further mediated by water molecules forming a column involving synthon II <italic>via</italic> O&#x2500;H&#x2219;&#x2219;&#x2219;O (1.842&#xa0;&#xc5; and 1.947&#xa0;&#xc5;). These columns further extend through C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; (3.173&#xa0;&#xc5; and 3.677&#xa0;&#xc5;) to the other two dimensions (<xref ref-type="fig" rid="F9">Figure 9</xref>). The reaction between Mef and <italic>4ap</italic> produced a salt hydrate <bold>12</bold>, which was recently reported by Trivedi et al. (<xref ref-type="bibr" rid="B27">Nechipadappu and Trivedi, 2017</xref>). Surprisingly, there is no acid-pyridine synthon observed in this structure; instead, the nitrogen of the pyridyl group of <italic>4ap</italic> interacted with the oxygen of the water molecule. The water mediates a pair of carboxylate dimers from two Mef, forming a tetramer via synthon II (<xref ref-type="fig" rid="F22">Scheme 4</xref>). The tetramers further interact with <italic>4ap</italic> through N&#x2500;H&#x2219;&#x2219;&#x2219;O (1.967&#xa0;&#xc5; and 2.001&#xa0;&#xc5;), forming a column. These columns are further linked to each other through synthon VII, C&#x2500;H&#x2219;&#x2219;&#x2219;O (2.523&#xa0;&#xc5;), C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; (3.132&#xa0;&#xc5;), and &#x3c0;&#x2219;&#x2219;&#x2219;&#x3c0; (3.640&#xa0;&#xc5;) interactions (<xref ref-type="fig" rid="F10">Figure 10</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<bold>(A)</bold> Nif&#x2500;<italic>2ap</italic> dimers interacted with other dimers via N&#x2500;H&#x2219;&#x2219;&#x2219;O to form a 1D Chain in <bold>4</bold>. <bold>(B)</bold> The chains are connected through C&#x2500;H&#x2219;&#x2219;&#x2219;F in the other two planes forming a 3D network.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g006.tif"/>
</fig>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>
<bold>(A)</bold> Interaction of Nif&#x2500;<italic>2ap</italic> dimers via N&#x2500;H&#x2219;&#x2219;&#x2219;O with other dimers to form a tetramer, in <bold>4a</bold>. <bold>(B)</bold> Stacking of tetramer through C&#x2212;H&#x2219;&#x2219;&#x2219;&#x3c0; interaction one over the other and cross-sects each other via C&#x2212;H&#x2219;&#x2219;&#x2219;F interaction to form a 3D structure.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g007.tif"/>
</fig>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>
<bold>(A)</bold> In <bold>6</bold>, Nif&#x2500;<italic>4ap</italic> dimers interacted with other dimers via N&#x2500;H&#x2219;&#x2219;&#x2219;O, forming a 1D Chain. <bold>(B)</bold> The chains are interconnected <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;F and C&#x2500;H&#x2219;&#x2219;&#x2219;O interaction in a perpendicular fashion.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g008.tif"/>
</fig>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>In <bold>10</bold>, The dimers of Mef&#x2500;<italic>2ap</italic> are connected with other dimers through N&#x2500;H&#x2219;&#x2219;&#x2219;O forming columns. These columns further connect with other columns via C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; to form a 3D network.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g009.tif"/>
</fig>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>
<bold>(A)</bold> In <bold>12</bold>, tetramers of Mef&#x2500;H<sub>2</sub>O&#x2500;Mef are formed <italic>via</italic> synthon II which further connected through N&#x2500;H&#x2219;&#x2219;&#x2219;O with other tetramers forming columns. <bold>(B)</bold> These columns, interacting with others <italic>via</italic> C&#x2500;H&#x2219;&#x2219;&#x2219;&#x3c0; and &#x3c0;&#x2219;&#x2219;&#x2219;&#x3c0; interactions, form a 3D network.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g010.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Hirshfeld Surface Analysis</title>
<p>Hirshfeld surfaces (HS) are frequently used to depict various types of interactions in multicomponent solids such as cocrystal, salt, hydrate or solvate and their polymorphs (<xref ref-type="bibr" rid="B35">Spackman and Jayatilaka, 2009</xref>). 2D finger plots derived from Hirshfeld surfaces of these solids are particularly helpful to compare intermolecular interactions that are not obvious in structurally similar compounds (<xref ref-type="bibr" rid="B35">Spackman and Jayatilaka, 2009</xref>). The fingerprint plots for all the solids prepared in this study were generated using di (distance from the surface to the nearest atom in the molecule) and de (distance from the surface to the nearest atom outside the molecule) as a pair of coordinates in an interval of 0.01&#xa0;&#xc5;, for each surface spot resulting in two-dimensional histograms. The Hirshfeld surface resulted in a 2D plot where different colors (blue to red) indicate different frequencies of the occurrence of interaction. Hirshfeld surfaces and 2D fingerprint plots of the monomorphic Nif (NIFLUM) and dimorphic Mef (XYNAC and XYNAC02) are shown in <xref ref-type="fig" rid="F11">Figures 11A&#x2013;J</xref>. The HS and fingerprint plots show the variation in the environment of the molecule, which dictates the structural difference. A comparison of Nif and Mef with the coformers <italic>bpe</italic> and <italic>bpee</italic> 2D fingerprint plots (<bold>1</bold>, <bold>2</bold>, <bold>2a, 7,</bold> and <bold>8</bold>) showed similar features (<xref ref-type="fig" rid="F12">Figures 12</xref>, <xref ref-type="fig" rid="F13">13</xref>). The 2D plots of <bold>1</bold>, <bold>2</bold>, <bold>2a, 7,</bold> and <bold>8</bold> show a single spike corresponding to N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N interaction histogram indicating the disruption of the acid-acid dimer of Nif and Mef <italic>via</italic> acid-pyridine synthon. Notice the absence of two spikes observed for carboxylic dimer in <xref ref-type="fig" rid="F11">Figure 11</xref>. Both Nif molecules present in the asymmetric unit of <bold>1</bold> showed a similar histogram except for a slight difference in F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions. The 2D fingerprint plots of Mef in <bold>7</bold> and <bold>8</bold> (<xref ref-type="fig" rid="F13">Figure 13</xref>) showed exactly similar features due to the isostructural nature of <bold>7</bold> and <bold>8.</bold> A comparison of 2D plots of Nif and Mef with the conformer <italic>bpp</italic> (<xref ref-type="fig" rid="F14">Figure 14</xref>) in <bold>3</bold> and <bold>9</bold> again showed the absence of the characteristic &#x201c;two spikes&#x201d; of O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O interaction and the presence of a single spike in N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N interaction due to carboxylic acid dimer disruption and acid-pyridine synthon formation. The difference in N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N histogram in <bold>3</bold> and <bold>9</bold> can be attributed to the difference in composition of acid and base in the solids. Solid <bold>3</bold> is a 2:1 acid-pyridine trimer, while <bold>9</bold> is an acid-pyridine dimer. The second nitrogen of <italic>bpp</italic> is involved in C&#x2212;H&#x2219;&#x2219;&#x2219;N interaction, as is inferred by the presence of shoulder in N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N histogram of <bold>9</bold> (<xref ref-type="fig" rid="F14">Figure 14G</xref>). The 2D fingerprint plots of Nif with the conformer <italic>2ap</italic> in solids <bold>4</bold> and <bold>4a</bold> and Mef in <bold>10</bold> (<xref ref-type="fig" rid="F15">Figure 15</xref>) showed the absence of N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N interaction; the presence of one single spike in O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O interaction histogram specifies the O&#x2219;&#x2219;&#x2219;H interaction, which is due to proton transfer from Nif and Mef to <italic>2ap</italic>. The C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C interaction histogram of Nif (<xref ref-type="fig" rid="F15">Figures 15C,G</xref>) is different in <bold>4</bold> and <bold>4a</bold> due to the difference in the extent of C&#x2212;H&#x2219;&#x2219;&#x2219;&#x3c0; bonding in these solids. The fingerprint plots of Nif and Mef in <bold>5</bold> and <bold>11</bold> are depicted in <xref ref-type="fig" rid="F16">Figure 16</xref> and in <bold>6</bold> and <bold>12</bold> in <xref ref-type="fig" rid="F17">Figure 17</xref>. The latter showed similar features of <bold>4</bold> and <bold>10,</bold> indicating the salt formation with <italic>4ap</italic>.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>
<bold>(A,E,H)</bold> Hirshfeld surface analysis and structural environment of Nif, Mef I, and Mef II. <bold>(B&#x2013;D)</bold> O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O, C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions resolved fingerprint plots of Nif. <bold>(F,G)</bold> and <bold>(I,J)</bold> O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O and C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C interactions resolved fingerprint plots of both forms of Mef. The two spikes present in the solids are characteristic of the carboxylic acid dimer.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g011.tif"/>
</fig>
<fig id="F12" position="float">
<label>FIGURE 12</label>
<caption>
<p>
<bold>(A&#x2013;D)</bold> O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions Resolved fingerprint plots of Nif in solid <bold>1</bold>, respectively. <bold>(E&#x2013;L)</bold> O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O and N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N interactions resolved fingerprint plots of Nif of solid <bold>2</bold> and <bold>2a</bold>, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g012.tif"/>
</fig>
<fig id="F13" position="float">
<label>FIGURE 13</label>
<caption>
<p>
<bold>(A&#x2013;F)</bold> Resolved fingerprint plots of Mef of <bold>7</bold> and <bold>8</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, and C&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;C interactions, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g013.tif"/>
</fig>
<fig id="F14" position="float">
<label>FIGURE 14</label>
<caption>
<p>
<bold>(A&#x2013;D)</bold> Resolved fingerprint plots of Nif of solid <bold>3</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, C&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;F interactions, respectively. <bold>(E&#x2013;G)</bold> Resolved fingerprint plots of Mef of solid <bold>9</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, and C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C interactions, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g014.tif"/>
</fig>
<fig id="F15" position="float">
<label>FIGURE 15</label>
<caption>
<p>
<bold>(A&#x2013;L)</bold> Resolved fingerprint plots of Nif in <bold>4</bold> and Nif I &#x26;Nif II in <bold>4a</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions, respectively. <bold>(M&#x2013;O)</bold> Resolved fingerprint plots of Mef of <bold>10</bold> in O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, and C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C interactions, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g015.tif"/>
</fig>
<fig id="F16" position="float">
<label>FIGURE 16</label>
<caption>
<p>
<bold>(A&#x2013;D)</bold> Resolved fingerprint plots of Nif in <bold>5</bold> in O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions, respectively. <bold>(E&#x2013;G)</bold> Resolved fingerprint plots of Mef in <bold>11</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, and C&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;C interactions, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g016.tif"/>
</fig>
<fig id="F17" position="float">
<label>FIGURE 17</label>
<caption>
<p>
<bold>(A&#x2013;D)</bold> Resolved fingerprint plots of Nif in <bold>6</bold> in O&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, C&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;C, and F&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;F interactions, respectively. <bold>(E&#x2013;G)</bold> Resolved fingerprint plots of Mef in <bold>12</bold> in O&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;O, N&#x2219;&#x2219;&#x2219;H/H&#x2219;&#x2219;&#x2219;N, and C&#x2219;&#x2219;&#x2219;H/ H&#x2219;&#x2219;&#x2219;C interactions, respectively.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g017.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Effect of p<italic>K</italic>a on Solid Forms</title>
<p>Crystallization of acid with a series based on structurally similar basic coformers &#x394;p<italic>K</italic>
<sub>a</sub>. The molecular salts for the carboxylic acid&#x2013;pyridine reaction have a COO&#x2219;&#x2219;&#x2219;provided a platform to explore the structural difference due to H&#x2013;N<sub>arom</sub> heterosynthon, while the cocrystals have a COO&#x2013;H&#x2219;&#x2219;&#x2219;N<sub>arom</sub> heterosynthon. Formation of a cocrystal or a salt is usually predicted by an empirical indicator, the &#x394;p<italic>K</italic>
<sub>a</sub> [&#x394;p<italic>K</italic>
<sub>a</sub> (base) &#x2212; &#x394;p<italic>K</italic>
<sub>a</sub> (acid)] rule. (<xref ref-type="bibr" rid="B31">Sarma et al., 2009</xref>; <xref ref-type="bibr" rid="B36">Stahl et al., 2011</xref>; <xref ref-type="bibr" rid="B22">Lemmerer et al., 2015</xref>). As a general rule, &#x394;p<italic>K</italic>
<sub>a</sub>&#x3c; 0 yields a cocrystal, while &#x394;p<italic>K</italic>
<sub>a</sub>&#x3e; 3.75 leads to a salt (<xref ref-type="bibr" rid="B6">Childs et al., 2007</xref>; <xref ref-type="bibr" rid="B9">Delori et al., 2013</xref>). It is generally believed that the cocrystal or salt, or both, can appear in the domain between 0 and 4, though proton transfer is unpredictable in this region (<xref ref-type="bibr" rid="B7">Cruz-Cabeza, 2012</xref>). We validated the &#x394;p<italic>K</italic>
<sub>a</sub> rule to all the multicomponent solids reported in this study as these were the products of acid and base. We found good agreement in all the cases. Solids which have &#x394;p<italic>K</italic>
<sub>a</sub> &#x2c3; 3.75 (<bold>4, 4a</bold>, <bold>5</bold>, <bold>6, 10</bold> and <bold>12</bold>) exclusively formed salts while solids with &#x394;p<italic>K</italic>a &#x2c2; 3.75 (<bold>1</bold>, <bold>2</bold>, <bold>2a</bold>, <bold>3</bold>, <bold>7</bold>, <bold>8, 9</bold> and <bold>11</bold>), resulted in the formation of a cocrystal. The data has been summarized in (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>The outcome of solids by p<italic>K</italic>a difference between Nif, Mef, and coformers.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">S. No.</th>
<th rowspan="2" align="center">NSAID</th>
<th rowspan="2" align="center">Coformer</th>
<th rowspan="2" align="center">&#x394;pKa &#x3d; [pKa(base) &#x2013; pKa(acid)]</th>
<th colspan="2" align="center">Solid form type</th>
</tr>
<tr>
<th align="center">Salt</th>
<th align="center">Cocrystal</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">Mef</td>
<td align="left">
<italic>bpee</italic>
</td>
<td align="char" char=".">4.99&#x2013;3.89 &#x3d; 1.1</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>8</bold>
</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Mef</td>
<td align="left">
<italic>bpe</italic>
</td>
<td align="char" char=".">5.32&#x2013;3.89 &#x3d; 1.43</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>7</bold>
</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">Mef</td>
<td align="left">
<italic>bpp</italic>
</td>
<td align="char" char=".">5.42&#x2013;3.89 &#x3d; 1.53</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>9</bold>
</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Mef</td>
<td align="left">
<italic>3ap</italic>
</td>
<td align="char" char=".">5.75&#x2013;3.89 &#x3d; 1.86</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>11</bold>
</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">Mef</td>
<td align="left">
<italic>2ap</italic>
</td>
<td align="char" char=".">6.82&#x2013;3.89 &#x3d; 2.93</td>
<td align="center">
<bold>10</bold>
</td>
<td align="left"/>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Nif</td>
<td align="left">
<italic>bpee</italic>
</td>
<td align="char" char=".">4.99&#x2013;1.89 &#x3d; 3.1</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>2, 2a</bold>
</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">Nif</td>
<td align="left">
<italic>bpe</italic>
</td>
<td align="char" char=".">5.32&#x2013;1.89&#x3d;3.43</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>1</bold>
</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">Nif</td>
<td align="left">
<italic>bpp</italic>
</td>
<td align="char" char=".">5.42&#x2013;1.89 &#x3d; 3.53</td>
<td align="center">&#x2014;</td>
<td align="center">
<bold>3</bold>
</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">Nif</td>
<td align="left">
<italic>3ap</italic>
</td>
<td align="char" char=".">5.75&#x2013;1.89 &#x3d; 3.86</td>
<td align="center">
<bold>5</bold>
</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">Nif</td>
<td align="left">
<italic>2ap</italic>
</td>
<td align="char" char=".">6.82&#x2013;1.89 &#x3d; 4.93</td>
<td align="center">
<bold>4, 4a</bold>
</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Mef</td>
<td align="left">
<italic>4ap</italic>
</td>
<td align="char" char=".">8.95&#x2013;3.89 &#x3d; 5.06</td>
<td align="center">
<bold>12</bold>
</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Nif</td>
<td align="left">
<italic>4ap</italic>
</td>
<td align="char" char=".">8.95&#x2013;1.89 &#x3d; 7.06</td>
<td align="center">
<bold>6</bold>
</td>
<td align="center">&#x2014;</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-5">
<title>Conformational Flexibility</title>
<p>Fenamates, due to their free rotation around the dihedral C&#x2012;C&#x2012;N&#x2012;C bond, showed conformational polymorphs. The flexibility of free Nif/Mef in its salts/cocrystals enables the molecule to show different conformations in the solid-state. Both Nif and Mef are very flexible molecules, as can be seen from <xref ref-type="table" rid="T4">Table 4</xref>. Their different conformations are depicted in an overlayed fashion in <xref ref-type="fig" rid="F18">Figure 18</xref>. Mef is dimorphic, while Nif is monomorphic. This conformational flexibility enabled Nif/Mef to form multicomponent solids with efficient hydrogen-bonding packing. The difference in torsion angles among all the solids based on Nif is evidence of its conformational flexibility. Two different Nif molecules in the asymmetric unit of <bold>1</bold> have almost equal torsion angles in the opposite direction. The torsion angles in Nif based solids although vary in different forms. In the case of Mef based solids, the torsion angle of <bold>8</bold> is close to Mef II, while in <bold>7</bold>, <bold>9</bold>, <bold>10</bold>, <bold>11,</bold> and <bold>12,</bold> it is different. To summarize, Nif based solids have torsion angles close to 0&#xb0; or parallel, while the Mef based solids have torsion angles close to 90&#xb0; or perpendicular. The ortho substitution in Mef could be the probable reason for this variation.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Torsional angles of Nif and Mef in the salt/cocrystal form and in the free state.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Nif based solids</th>
<th align="center">Nif</th>
<th align="center">
<bold>1</bold>
</th>
<th align="center">
<bold>2</bold>
</th>
<th align="center">
<bold>2a</bold>
</th>
<th align="center">
<bold>3</bold>
</th>
<th align="center">
<bold>4</bold>
</th>
<th align="center">
<bold>4a</bold>
</th>
<th align="center">
<bold>5</bold>
</th>
<th align="center">
<bold>6</bold>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">&#x3c4;</td>
<td align="char" char=".">&#x2013;4.62</td>
<td align="char" char=".">17.66, &#x2013;18.70</td>
<td align="char" char=".">17.98</td>
<td align="char" char=".">33.03</td>
<td align="char" char=".">11.90</td>
<td align="char" char=".">&#x2013;5.92</td>
<td align="char" char=".">24.76</td>
<td align="char" char=".">&#x2014;</td>
<td align="char" char=".">&#x2013;7.45</td>
</tr>
<tr>
<td align="left">
<bold>Mef based solids</bold>
</td>
<td align="center">
<bold>Mef I</bold>
</td>
<td align="center">
<bold>Mef II</bold>
</td>
<td align="center">
<bold>7</bold>
</td>
<td align="center">
<bold>8</bold>
</td>
<td align="center">
<bold>9</bold>
</td>
<td align="center">
<bold>10</bold>
</td>
<td align="center">
<bold>11</bold>
</td>
<td align="center">
<bold>12</bold>
</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x3c4;</td>
<td align="char" char=".">&#x2013;119.98</td>
<td align="char" char=".">&#x2212;80.82</td>
<td align="char" char=".">90.35</td>
<td align="char" char=".">&#x2212;91.97</td>
<td align="char" char=".">74.66</td>
<td align="char" char=".">76.05</td>
<td align="center">&#x2014;</td>
<td align="char" char=".">94.73</td>
<td align="center">&#x2014;</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F18" position="float">
<label>FIGURE 18</label>
<caption>
<p>
<bold>(A)</bold> Molecular overlay diagrams of Nif in salts/cocrystals. Color codes: Light blue&#x2012;Nif, Red&#x2012;<bold>1</bold>, Orange&#x2012;<bold>2</bold>, Yellow&#x2012;<bold>2a</bold>, Green&#x2012;<bold>3</bold>, Cyan&#x2012;<bold>4</bold>, Blue&#x2012;<bold>4a</bold>, Purple&#x2012;<bold>5</bold>, Magenta&#x2012;<bold>6</bold>. <bold>(B)</bold> Molecular overlay diagrams of Mef molecule in salts/cocrystals. Color codes: Light blue&#x2012;Mef I, Green&#x2012;Mef II, Red&#x2012;<bold>7</bold>, Orange&#x2012;<bold>8</bold>, Yellow&#x2012;<bold>9</bold>, Cyan&#x2012;<bold>10</bold>, Blue&#x2012;<bold>11</bold>, Purple&#x2012;<bold>12</bold>.</p>
</caption>
<graphic xlink:href="fchem-10-729608-g018.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Crystallization of Six Selected Anthranilic Acid Based NSAIDs (A) With N-Containing Coformers (B)</title>
<p>CSD analysis of the six selected anthranilic acid based NSAIDs (A) with N-containing co-formers (B) solids (<xref ref-type="sec" rid="s9">Supplementary Scheme S1</xref>, <xref ref-type="sec" rid="s9">Supplementary Tables S1, S2</xref>), led to the following conclusions based on the structural features. 4,4&#x2032;-bipy is the only reported coformer that formed 2:1 cocrystal (A<sub>2</sub>B) with all the six acids surveyed here. Interestingly the crystal structures of all the six solids were dominated by the trimeric acid pyridine synthon (A&#x660;&#x660;&#x660;B&#x660;&#x660;&#x660;A) as observed in all bipyridine solids (<bold>1</bold>, <bold>2</bold>, <bold>2a</bold>, <bold>3</bold>, <bold>7</bold> and <bold>8</bold>) reported here except solid <bold>9</bold>. As expected, 4,4&#x2032;-azopyridine is also reported to form a cocrystal with composition A<sub>2</sub>B. In the case of reaction with <italic>bpee</italic>, we obtained a cocrystal solvate concomitantly. The solid <bold>9</bold> (AFOPAP) showed a rare coformer-coformer homosynthon (synthon VII in <xref ref-type="fig" rid="F22">Scheme 4</xref>) which could be a contributing factor towards its composition of 1:1 (<xref ref-type="bibr" rid="B43">Zheng et al., 2018</xref>).</p>
<p>Monopyridine containing solids such as acridine, methyl, chloro or amide substituted pyridine invariably led to anhydrous 1:1 cocrystals. The solvent DMF, sulfamethazine and pyridine-2-one all formed 1:1 solid. An interesting addition the cocrystal <bold>11</bold> formed between Mef (<italic>p</italic>Ka &#x3d; 5.75) and <italic>3ap</italic>. The same coformer, however, yielded a 1:1 salt (solid <bold>5</bold>) with <italic>Nif</italic>. All coformers containing a single amino group formed only 1:1 salt with fenamic acids. Piperazine (more basic one) is the only coformer that showed both 2:1 and 1:1 salts and hydrates with the acids, <italic>Mef</italic>, <italic>Tol</italic> and <italic>Mec</italic>. The two cyclic tetramine and ethylenediamine gets easily diprotonated and hence formed salts of the composition, AB<sub>2</sub>
<sup>.</sup> Only three salts with refcodes <ext-link ext-link-type="uri" xlink:href="https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=BEBGOH&amp;DatabaseToSearch=Published">BEBGOH</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=ZAZGEO&amp;DatabaseToSearch=Published">ZAZGEO</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=JUDPUW&amp;DatabaseToSearch=Published">JUDPUW</ext-link> showed a deviation in composition with the occurrence of <italic>AB</italic>
<sub>
<italic>2</italic>
</sub> for the first two and A<sub>2</sub>B for the last one. The three examples suggested that apart from charge balance (e.g. A<sup>&#x2212;</sup>B<sup>&#x2b;</sup>), microscopic stabilization of the building blocks (dimer, trimer, etc) could lead to inclusion of a neutral coformer as in AB<sub>2</sub> or A<sub>2</sub>B or solvent in the final outcome of the crystallization.</p>
<p>It was observed that, statistically, ortho substituted fenamates, namely, Mefenamic acid (Mef), Tolfenamic acid (Tol), and Meclofenamic acid (Mec), showed higher tendency (39, 41 and 33%, respectively) to form solvates than Flufenamic acid (Flu) and Niflumic Acid (Nif) (18 and 10% respectively). It should be noted that Flu and Nif have higher chance of free rotation around the dihedral angle for better packing efficiency; this conformational rotation is restricted in Mef, Tol and Mec due to ortho substitution. The two acids, a sulfonic and maleic formed 1:1 salt with a protonated <italic>Nif</italic> with a favorable -COO&#x660;&#x660;&#x660;H&#x2212;N (py).</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>The present study demonstrates the robustness of acid&#x2219;&#x2219;&#x2219;pyridine synthon to design new cocrystals, salts, salt-cocrystals, and salt hydrates based on Nif and Mef. The presence of conformational flexibility enables Nif/Mef to form multicomponent solids with efficient hydrogen-bonding packing. The Nif molecules present in the asymmetric unit of <bold>1</bold> showed two confirmations having almost equal torsion angles in the opposite direction. To compare, torsion angles of Nif based solids are close to 0&#xb0; or parallel, while the Mef based solids have torsion angles close to 90&#xb0; or perpendicular. This variation can probably be ascribed to the ortho substitution in Mef. The stoichiometry of the resulting solids is governed by conformational flexibility and/or supramolecular aggregation. The structural differences of Nif and Mef based solids are discussed via fingerprint plots generated through Hirshfeld surface analysis. The impact of &#x394;p<italic>K</italic>a has been discussed and validated on Nif and Mef based solids. Apart from the two bipyridine based solids (<bold>1</bold> and <bold>2</bold>), relative solubilities of the solids showed an increase compared to their respective fenamates.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s9">Supplementary Material</xref>.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>AR conceived the idea as he has been working in this field for over 25&#xa0;years. VK has a lead role in designing the synthesis and characterization of the solids. PG supported in synthesis and data collection. Balendra helped in the refinement of crystal structures and supported in data collection and analysis. ST helped in data analysis, carried out the literature analysis and reviewing tasks.</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>VK, PG, and Balendra acknowledge UGC for a research fellowship. ST and AR acknowledge DST, Government of India, for financial support and powder and single-crystal X-ray diffraction facility (DST: SR/FST/CSII-07/2014) to the Department of Chemistry, IIT Delhi, India.</p>
</ack>
<sec id="s9">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchem.2022.729608/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchem.2022.729608/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet3.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM2" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet2.docx" id="SM3" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhattacharya</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Soni</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>C. M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Screening, crystal Structures and Solubility Studies of a Series of Multidrug Salt Hydrates and Cocrystals of Fenamic Acids with Trimethoprim and Sulfamethazine</article-title>. <source>J. Mol. Struct.</source> <volume>1199</volume>, <fpage>127028</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2019.127028</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodn&#xe1;r</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Rasmuson</surname>
<given-names>&#xc5;. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Stepwise Use of Additives for Improved Control over Formation and Stability of Mefenamic Acid Nanocrystals Produced by Antisolvent Precipitation</article-title>. <source>Cryst. Growth Des.</source> <volume>17</volume>, <fpage>454</fpage>&#x2013;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1021/acs.cgd.6b01256</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>B. L.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Treatment of Menorrhagia during Menstruation: Randomised Controlled Trial of Ethamsylate, Mefenamic Acid, and Tranexamic Acid</article-title>. <source>BMJ</source> <volume>313</volume>, <fpage>579</fpage>&#x2013;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.313.7057.579</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="book">
<collab>Bruker Analytical X-ray Systems</collab> (<year>2000</year>). <source>SMART: Bruker Molecular Analysis Research Tool</source>. <publisher-loc>Madison, WI</publisher-loc>: <publisher-name>Bruker AXS</publisher-name>. </citation>
</ref>
<ref id="B5">
<citation citation-type="book">
<collab>Bruker Analytical X-ray Systems, SAINT-NT</collab> (<year>2001</year>). <source>Bruker Analytical X-ray Systems. SAINT &#x2b; NT, Version 6.04</source>. <publisher-loc>Madison, WI</publisher-loc>. <publisher-name>Bruker AXS</publisher-name>. </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Childs</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Stahly</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The Salt&#x2212;Cocrystal Continuum: The Influence of Crystal Structure on Ionization State</article-title>. <source>Mol. Pharmaceutics</source> <volume>4</volume>, <fpage>323</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1021/mp0601345</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coelho</surname>
<given-names>A. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>TOPAS and TOPAS-Academic: An Optimization Program Integrating Computer Algebra And Crystallographic Objects Written in C&#x2b;&#x2b;</article-title>. <source>J. Appl. Cryst.</source> <volume>51</volume>, <fpage>210</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1107/S1600576718000183</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruz-Cabeza</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Acid-base Crystalline Complexes and the pKa Rule</article-title>. <source>CrystEngComm</source> <volume>14</volume>, <fpage>6362</fpage>. <pub-id pub-id-type="doi">10.1039/c2ce26055g</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delaney</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Korter</surname>
<given-names>T. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Conformational Origins of Polymorphism in Two Forms of Flufenamic Acid</article-title>. <source>J. Mol. Struct.</source> <volume>1078</volume>, <fpage>83</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2014.02.001</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delori</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Galek</surname>
<given-names>P. T. A.</given-names>
</name>
<name>
<surname>Pidcock</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Patni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Knowledge-based Hydrogen Bond Prediction and the Synthesis of Salts and Cocrystals of the Anti-malarial Drug Pyrimethamine with Various Drug and GRAS Molecules</article-title>. <source>CrystEngComm</source> <volume>15</volume>, <fpage>2916</fpage>. <pub-id pub-id-type="doi">10.1039/c3ce26765b</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dionne</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Berthold</surname>
<given-names>C. W.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Therapeutic Uses of Non-steroidal Anti-inflammatory Drugs in Dentistry</article-title>. <source>Crit. Rev. Oral Biol. Med.</source> <volume>12</volume>, <fpage>315</fpage>&#x2013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1177/10454411010120040301</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolomanov</surname>
<given-names>O. V.</given-names>
</name>
<name>
<surname>Bourhis</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Gildea</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>J. A. K.</given-names>
</name>
<name>
<surname>Puschmann</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>OLEX2: a Complete Structure Solution, Refinement and Analysis Program</article-title>. <source>J. Appl. Cryst.</source> <volume>42</volume>, <fpage>339</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1107/S0021889808042726</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Azim</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Challenges and Opportunities of Pharmaceutical Cocrystals: a Focused Review on Non-steroidal Anti-inflammatory Drugs</article-title>. <source>RSC Med. Chem.</source> <volume>12</volume>, <fpage>705</fpage>&#x2013;<lpage>721</lpage>. <pub-id pub-id-type="doi">10.1039/D0MD00400F</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goswami</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ramanan</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Multicomponent Solids of Diclofenac with Pyridine Based Coformers</article-title>. <source>J. Mol. Struct.</source> <volume>1210</volume>, <fpage>128066</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128066</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenstein</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Lew</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dickenson</surname>
<given-names>E. R. V.</given-names>
</name>
<name>
<surname>Wert</surname>
<given-names>E. C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Investigation of Biotransformation, Sorption, and Desorption of Multiple Chemical Contaminants in Pilot-Scale Drinking Water Biofilters</article-title>. <source>Chemosphere</source> <volume>200</volume>, <fpage>248</fpage>&#x2013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1016/j.chemosphere.2018.02.107</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higuchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>K. A.</given-names>
</name>
</person-group> (<year>1965</year>). <article-title>Phase Solubility Techniques</article-title>. <source>Adv. Anal. Chem. Instrumentation</source> <volume>4</volume>, <fpage>117</fpage>&#x2013;<lpage>212</lpage>. </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roy Choudhury</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Salts of Amoxapine with Improved Solubility for Enhanced Pharmaceutical Applicability</article-title>. <source>ACS Omega</source> <volume>3</volume>, <fpage>2406</fpage>&#x2013;<lpage>2416</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.7b02023</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karanam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Structural Landscape of Pure Enrofloxacin and its Novel Salts: Enhanced Solubility for Better Pharmaceutical Applicability</article-title>. <source>Cryst. Growth Des.</source> <volume>13</volume>, <fpage>1626</fpage>&#x2013;<lpage>1637</lpage>. <pub-id pub-id-type="doi">10.1021/cg301831s</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khansari</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Halliwell</surname>
<given-names>R. F.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Evidence for Neuroprotection by the Fenamate NSAID, Mefenamic Acid</article-title>. <source>Neurochem. Int.</source> <volume>55</volume>, <fpage>683</fpage>&#x2013;<lpage>688</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2009.06.014</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Goswami</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Thaimattam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ramanan</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Multicomponent Solids of Uracil Derivatives - Orotic and Isoorotic Acids</article-title>. <source>CrystEngComm</source> <volume>20</volume>, <fpage>3490</fpage>&#x2013;<lpage>3504</lpage>. <pub-id pub-id-type="doi">10.1039/C8CE00486B</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemmerer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Govindraju</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Motloung</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Savig</surname>
<given-names>K. L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Co-crystals and Molecular Salts of Carboxylic Acid/pyridine Complexes: Can Calculated pKa&#x27;s Predict Proton Transfer? A Case Study of Nine Complexes</article-title>. <source>CrystEngComm</source> <volume>17</volume>, <fpage>3591</fpage>&#x2013;<lpage>3595</lpage>. <pub-id pub-id-type="doi">10.1039/C5CE00102A</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf3;pez-Mej&#xed;as</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kampf</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Matzger</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Nonamorphism in Flufenamic Acid and a New Record for a Polymorphic Compound with Solved Structures</article-title>. <source>J. Am. Chem. Soc.</source> <volume>134</volume>, <fpage>9872</fpage>&#x2013;<lpage>9875</lpage>. <pub-id pub-id-type="doi">10.1021/ja302601f</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf3;pez-Mej&#xed;as</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Matzger</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Structure-Polymorphism Study of Fenamates: Toward Developing an Understanding of the Polymorphophore</article-title>. <source>Cryst. Growth Des.</source> <volume>15</volume>, <fpage>3955</fpage>&#x2013;<lpage>3962</lpage>. <pub-id pub-id-type="doi">10.1021/acs.cgd.5b00570</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margot</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Holliger</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>A Review of the Fate of Micropollutants in Wastewater Treatment Plants</article-title>. <source>WIREs Water</source> <volume>2</volume>, <fpage>457</fpage>&#x2013;<lpage>487</lpage>. <pub-id pub-id-type="doi">10.1002/wat2.1090</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mila</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nika</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Thomaidis</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Identification of First and Second Generation Ozonation Transformation Products of Niflumic Acid by LC-QToF-MS</article-title>. <source>J. Hazard. Mater.</source> <volume>365</volume>, <fpage>804</fpage>&#x2013;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhazmat.2018.11.046</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nechipadappu</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Structural and Physicochemical Characterization of Pyridine Derivative Salts of Anti-inflammatory Drugs</article-title>. <source>J. Mol. Struct.</source> <volume>1141</volume>, <fpage>64</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2017.03.086</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Putz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Brandenburg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kreuzherrenstr</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>nd</year>). <article-title>Diamond - Crystal and Molecular Structure Visualization</article-title>. <source>Crystal Impact</source> <volume>102</volume>, <fpage>53227</fpage>. <comment>Available at:<ext-link ext-link-type="uri" xlink:href="https://www.crystalimpact.de/diamond">https://www.crystalimpact.de/diamond</ext-link>
</comment>. </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radacsi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ambrus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Szab&#xf3;-R&#xe9;v&#xe9;sz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>van der Heijden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>ter Horst</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2012a</year>). <article-title>Atmospheric Pressure Cold Plasma Synthesis of Submicrometer-Sized Pharmaceuticals with Improved Physicochemical Properties</article-title>. <source>Cryst. Growth Des.</source> <volume>12</volume>, <fpage>5090</fpage>&#x2013;<lpage>5095</lpage>. <pub-id pub-id-type="doi">10.1021/cg301026b</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radacsi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ambrus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Szunyogh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Szab&#xf3;-R&#xe9;v&#xe9;sz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stankiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>van der Heijden</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2012b</year>). <article-title>Electrospray Crystallization for Nanosized Pharmaceuticals with Improved Properties</article-title>. <source>Cryst. Growth Des.</source> <volume>12</volume>, <fpage>3514</fpage>&#x2013;<lpage>3520</lpage>. <pub-id pub-id-type="doi">10.1021/cg300285w</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radacsi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>ter Horst</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Stefanidis</surname>
<given-names>G. D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Microwave-Assisted Evaporative Crystallization of Niflumic Acid for Particle Size Reduction</article-title>. <source>Cryst. Growth Des.</source> <volume>13</volume>, <fpage>4186</fpage>&#x2013;<lpage>4189</lpage>. <pub-id pub-id-type="doi">10.1021/cg4010906</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Bhogala</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Nangia</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Synthon Competition and Cooperation in Molecular Salts of Hydroxybenzoic Acids and Aminopyridines</article-title>. <source>Cryst. Growth Des.</source> <volume>9</volume>, <fpage>1546</fpage>&#x2013;<lpage>1557</lpage>. <pub-id pub-id-type="doi">10.1021/cg801145c</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1973</year>). <article-title>A Summary of the Acute Toxicity of 4-aminopyridine to Birds and Mammals</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>26</volume>, <fpage>532</fpage>&#x2013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1016/0041-008X(73)90291-3</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>SeethaLekshmi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guru Row</surname>
<given-names>T. N.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Conformational Polymorphism in a Non-steroidal Anti-inflammatory Drug, Mefenamic Acid</article-title>. <source>Cryst. Growth Des.</source> <volume>12</volume>, <fpage>4283</fpage>&#x2013;<lpage>4289</lpage>. <pub-id pub-id-type="doi">10.1021/cg300812v</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shoji</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Morishita</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). &#x201c;<article-title>Pyridine and Pyridine Derivatives</article-title>,&#x201d; in <source>Ullmann&#x2019;s Encyclopedia of Industrial Chemistry</source> (<publisher-loc>Weinheim, Germany</publisher-loc>: <publisher-name>Wiley-VCH Verlag GmbH &#x26; Co. KGaA</publisher-name>). <pub-id pub-id-type="doi">10.1002/14356007.a22_399</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spackman</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Jayatilaka</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Hirshfeld Surface Analysis</article-title>. <source>CrystEngComm</source> <volume>11</volume>, <fpage>19</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1039/B818330A</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Wermuth</surname>
<given-names>C. G.</given-names>
</name>
</person-group>
<collab>International Union of Pure and Applied Chemistry</collab> (<year>2011</year>). <source>Handbook of Pharmaceutical Salts: Properties, Selection, and Use</source>. <edition>2nd rev</edition> (<publisher-loc>Weinheim</publisher-loc>: <publisher-name>Wiley VCH</publisher-name>). </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sturkenboom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nicolosi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cantarutti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mannino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Picelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scamarcia</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Incidence of Mucocutaneous Reactions in Children Treated with Niflumic Acid, Other Nonsteroidal Antiinflammatory Drugs, or Nonopioid Analgesics</article-title>. <source>PEDIATRICS</source> <volume>116</volume>, <fpage>e26</fpage>&#x2013;<lpage>e33</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2004-0040</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sydnes</surname>
<given-names>O. A.</given-names>
</name>
</person-group> (<year>1973</year>). <article-title>A Clinical Investigation of Niflumic Acid in the Treatment of Rheumatoid Arthritis</article-title>. <source>Scand. J. Rheumatol.</source> <volume>2</volume>, <fpage>8</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.3109/03009747309095202</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szunyogh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ambrus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Szab&#xf3;-R&#xe9;v&#xe9;sz</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Nanonization of Niflumic Acid by Co-grinding</article-title>. <source>ANP</source> <volume>02</volume>, <fpage>329</fpage>&#x2013;<lpage>335</lpage>. <pub-id pub-id-type="doi">10.4236/anp.2013.24045</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uyemura</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Mingatto</surname>
<given-names>F. E.</given-names>
</name>
<name>
<surname>Jordani</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Curti</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Diclofenac Sodium and Mefenamic Acid: Potent Inducers of the Membrane Permeability Transition in Renal Cortex Mitochondria</article-title>. <source>Arch. Biochem. Biophys.</source> <volume>342</volume>, <fpage>231</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1006/abbi.1997.9985</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uzoh</surname>
<given-names>O. G.</given-names>
</name>
<name>
<surname>Cruz-Cabeza</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Is the Fenamate Group a Polymorphophore? Contrasting the Crystal Energy Landscapes of Fenamic and Tolfenamic Acids</article-title>. <source>Cryst. Growth Des.</source> <volume>12</volume>, <fpage>4230</fpage>&#x2013;<lpage>4239</lpage>. <pub-id pub-id-type="doi">10.1021/cg3007348</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wittering</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Agnew</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Klapwijk</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cousen</surname>
<given-names>A. J. P.</given-names>
</name>
<name>
<surname>Cruickshank</surname>
<given-names>D. L.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Crystallisation and Physicochemical Property Characterisation of Conformationally-Locked Co-crystals of Fenamic Acid Derivatives</article-title>. <source>CrystEngComm</source> <volume>17</volume>, <fpage>3610</fpage>&#x2013;<lpage>3618</lpage>. <pub-id pub-id-type="doi">10.1039/C5CE00297D</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Rood</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Unruh</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Hutchins</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Co-crystallization of Anti-inflammatory Pharmaceutical Contaminants and Rare Carboxylic Acid-Pyridine Supramolecular Synthon Breakdown</article-title>. <source>CrystEngComm</source> <volume>20</volume>, <fpage>6377</fpage>&#x2013;<lpage>6381</lpage>. <pub-id pub-id-type="doi">10.1039/C8CE01492B</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>